Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC discusses the use of PARP Inhibitors and in combination with Anti-VEGF, Chemotherapy, and Immunotherapy Agents. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.
PARP Inhibitors May Soon Be Combined with Anti-VEGF, Chemotherapy, and Immunotherapy Agents
